Neurizon Therapeutics (ASX: NUZ) has successfully raised over $44 million AUD through a multi-pronged capital raise, securing funding to advance its lead drug candidate NUZ-001 through the HEALEY ALS Platform Trial and into early 2026.
Capital Boosted by Multiple Sources
Neurizon secured approximately $7.1 million AUD via a placement, issuing shares at $0.08 each. This placement attracted strong support, with approximately 89.1 million new shares issued.
Further bolstering its balance sheet, the company established a $20 million AUD convertible note facility with Obsidian Global, LLC. The initial drawdown from this facility amounted to $5 million AUD, providing immediate capital. This facility is structured for a term of over two years.
To offer existing shareholders an opportunity to participate, Neurizon is also undertaking a 2-for-5 pro rata non-renounceable entitlement offer, aiming to raise up to an additional $17.1 million AUD.
Funding for Critical NUZ-001 Trial
The capital raised is specifically designated to fund the development of NUZ-001 in the crucial HEALEY ALS Platform Trial. This trial is a significant step forward for the lead drug candidate.
This substantial funding ensures Neurizon has the necessary capital to advance NUZ-001 through the trial stages and extends its operational runway well into early 2026.
The company anticipates that the first patient dosing in the HEALEY ALS Platform Trial will occur in early 2026, marking a key milestone for the program.
Strategic Financial Maneuver
Demonstrating confidence in the company's direction, Neurizon's Directors and Management participated in the recent placement, contributing approximately $0.8 million AUD to the capital raise.
This strategic capital raise is expected to accelerate potential global regulatory pathways, partnering opportunities, and commercialisation prospects for NUZ-001.
Previous coverage has highlighted NUZ-001's potential as a platform therapy for both ALS and Huntington's disease, supported by preclinical data showing its effective ability to cross the blood-brain barrier. Studies in June 2025 confirmed its significant blood–brain barrier penetration, while positive results from an independent study in April 2025 on a 3D human brain model further demonstrated NUZ-001's strong safety characteristics.
Investor Considerations
The substantial capital raise significantly de-risks Neurizon's near-term execution by providing runway into early 2026 for the HEALEY ALS trial. Investors will monitor the success of the entitlement offer and the progression of NUZ-001 through clinical development, with potential dilution from the placement and offer being a near-term consideration.
